In 2018, Shen et al. demonstrated that PCI-34051 (1), in combination with the anaplastic lymphoma kinase/tyrosine-protein kinase Met (ALK/MET) inhibitor crizotinib, efficiently inhibited the activation of growth receptor survival signalling, leading to cell cycle arrest in neuroblastoma cell lines and reducing tumour cell growth in a zebrafish xenograft model [112]. The gene discussed is ALK; the disease is neoplasm.